参芪扶正注射液联合FOLFOX4方案化疗治疗晚期胃癌的疗效  

Curative Effect of Shenqi Fuzheng Injection Combined with FOLFOX4 Chemotherapy on Advanced Gastric Cancer

作　　者：王娟 田宁 刘超 宫慧敏 WANG Juan;TIAN Ning;LIU Chao;GONG Huimin(Department of ChemotherapyⅡ,Tai'an Cancer Prevention and Treatment Hospital,Tai'an 271000,Shandong,China;Department of Special Examination,Tai'an Cancer Prevention and Treatment Hospital,Tai'an 271000,Shandong,China)

机构地区：[1]泰安市肿瘤防治院化疗二科,山东泰安271000 [2]泰安市肿瘤防治院特检科,山东泰安271000

出　　处：《世界复合医学》2024年第6期45-49,共5页World Journal of Complex Medicine

摘　　要：目的研究参芪扶正注射液联合FOLFOX4方案化疗治疗晚期胃癌的疗效。方法选取2022年2月—2023年10月泰安市肿瘤防治院收治的90例晚期胃癌患者为研究对象,按治疗方法不同分为对照组(n=45,FOLFOX4方案化疗治疗)和研究组(n=45,参芪扶正注射液联合FOLFOX4方案化疗治疗)。比较两组治疗效果、血清肿瘤标志物表达水平、T淋巴细胞亚群水平、不良反应发生率。结果研究组治疗总有效率为82.22%(37/45),明显高于对照组62.22%(28/45),差异有统计学意义(χ^(2)=5.954,P=0.015)。治疗后,研究组各血清肿瘤标志物水平低于对照组,差异有统计学意义(P均<0.05)。治疗后,研究组各T淋巴细胞亚群水平均高于对照组,差异有统计学意义(P均<0.05)。研究组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论对于采取FOLFOX4方案化疗治疗的晚期胃癌患者,加用参芪扶正注射液能够获得更加理想的治疗效果,可以进一步下调肿瘤标志物表达水平,帮助患者提高机体免疫功能,减少不良反应的发生。Objective To study the curative effect of Shenqi Fuzheng Injection combined with FOLFOX4 chemotherapy in the treatment of advanced gastric cancer.Methods A total of 90 patients with advanced gastric cancer admitted to Tai'an Cancer Prevention and Treatment Hospital from February 2022 to October 2023 were selected as the research objects.They were divided into control group(n=45,FOLFOX4 regimen chemotherapy)and study group(n=45,Shenqi Fuzheng Injection combined with FOLFOX4 regimen chemotherapy)according to different treatment methods.The therapeutic effect,serum tumor marker expression levels,T lymphocyte subsets levels and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 82.22%(37/45),which was significantly higher than 62.22%(28/45)of the control group,and the difference was statistically significant(χ^(2)=5.954,P=0.015).After treatment,the levels of serum tumor markers in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of T lymphocyte subsets in the study group were higher than those in the control group,and the differences were statistically significant(all P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with advanced gastric cancer treated with FOLFOX4 chemotherapy regimen,Shenqi Fuzheng Injection can achieve more ideal therapeutic effect,further reduce the expression level of tumor markers,help patients improve the immune function of the body and reduce the occurrence of adverse reactions.

关 键 词：参芪扶正注射液 FOLFOX4方案 晚期胃癌 肿瘤标志物 免疫功能 

分 类 号：R735[医药卫生—肿瘤]